FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mohamed Rahmani

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Disorders

Leukemia

Co-author Network

Publications

TOP 3
Mohamed Rahmani; David C Williams; Elisa Attkisson; Mandy Mayo Aust; Andrea Ferreira-Gonzalez; Steven Grant
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Prithviraj Bose; Mohamed Rahmani; Steven Grant
Coordinate PI3K pathway and Bcl-2 family disruption in AML.
Bridget A Quinn; Mohamed Rahmani; John C Reed; Devanand Sarkar; Siddik Sarkar; John L Stebbins; Jun Wei; Bainan Wu; Belal Azab; David T Curiel; Swadesh K Das; Santanu Dasgupta; Rupesh Dash; Paul Dent; Igor Dmitriev; Steven Grant; Michael Hedvat; Sachin Kumar; Regina A Oyesanya; Maurizio Pellecchia; Paul B Fisher
Targeting Mcl-1 for the therapy of cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mohamed Rahmani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mohamed Rahmani; David C Williams; Elisa Attkisson; Mandy Mayo Aust; Andrea Ferreira-Gonzalez; Steven Grant
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer research 2013;73(4):1340-51.
2012: Prithviraj Bose; Mohamed Rahmani; Steven Grant
Coordinate PI3K pathway and Bcl-2 family disruption in AML.
Oncotarget 2012;3(12):1499-500.
2011: Bridget A Quinn; Mohamed Rahmani; John C Reed; Devanand Sarkar; Siddik Sarkar; John L Stebbins; Jun Wei; Bainan Wu; Belal Azab; David T Curiel; Swadesh K Das; Santanu Dasgupta; Rupesh Dash; Paul Dent; Igor Dmitriev; Steven Grant; Michael Hedvat; Sachin Kumar; Regina A Oyesanya; Maurizio Pellecchia; Paul B Fisher
Targeting Mcl-1 for the therapy of cancer.
Expert opinion on investigational drugs 2011;20(10):1397-411.
2011: Rupesh Dash; Belal Azab; Bridget A Quinn; Xuening Shen; Xiang-Yang Wang; Swadesh K Das; Mohamed Rahmani; Jun Wei; Michael Hedvat; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Bainan Wu; John L Stebbins; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(21):8785-90.
2010: Mohamed Rahmani; Mandy Mayo; Rupesh Dash; Upneet Kaur Sokhi; Igor P Dmitriev; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.
Molecular pharmacology 2010;78(6):1096-104.
2010: Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Xiang-Yang Wang; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej S Lesniak; Steven Grant; David T Curiel; Paul B Fisher
The development of MDA-7/IL-24 as a cancer therapeutic.
Pharmacology & therapeutics 2010;128(2):375-84.
2010: Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.
Anti-cancer drugs 2010;21(8):725-31.
2010: Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel Johnson; Paul B Fisher; Steven Grant; Paul Dent
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Molecular cancer therapeutics 2010;9(5):1378-95.
2009: Aditi Pandya Martin; Clint Mitchell; Mohamed Rahmani; Kenneth P Nephew; Steven Grant; Paul Dent
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Cancer biology & therapy 2009;8(21):2084-96.
2009: Aditi Pandya Martin; Margaret A Park; Clint Mitchell; Teneille Walker; Mohamed Rahmani; Andrew Thorburn; Dieter Häussinger; Roland Reinehr; Steven Grant; Paul Dent
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Molecular pharmacology 2009;76(2):327-41.
2009: Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Martin Graf; Mohamed Rahmani; Peter J Houghton; Christina Voelkel Johnson; Steven Grant; Paul Dent
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Molecular pharmacology 2009;76(2):342-55.
2009: Margaret A Park; Teneille Walker; Aditi Pandya Martin; Jeremy C Allegood; Nicollaq Vozhilla; Luni Emdad; Devanand Sarkar; Mohamed Rahmani; Martin Graf; Adly Yacoub; Constantinos Koumenis; Sarah Spiegel; David T Curiel; Christina Voelkel Johnson; Steven Grant; Paul B Fisher; Paul Dent
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.
Molecular cancer therapeutics 2009;8(5):1280-91.
2009: Girija Dasmahapatra; Dmitry Lembersky; Mohamed Rahmani; Lora Kramer; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Cancer biology & therapy 2009;8(9):808-19.
2008: Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Phillip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Cancer biology & therapy 2008;7(10):1648-62.
2008: Guo Zhang; Margaret A Park; Clint Mitchell; Teneille Walker; Hossein Hamed; Elaine Studer; Martin Graf; Mohamed Rahmani; Seema Gupta; Phillip B Hylemon; Paul B Fisher; Steven Grant; Paul Dent
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.
The Journal of biological chemistry 2008;283(36):24343-58.
2008: Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Molecular cancer therapeutics 2008;7(9):2633-48.
2008: Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5385-99.
2008: Aditi Pandya Martin; Anna Miller; Luni Emad; Mohamed Rahmani; Teneille Walker; Clint Mitchell; Michael P Hagan; Margaret A Park; Adly Yacoub; Paul B Fisher; Steven Grant; Paul Dent
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Molecular pharmacology 2008;74(3):807-22.
2008: Steven W Paugh; Barbara S Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey K Adams; Robert E Zipkin; Steven Grant; Sarah Spiegel
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Blood 2008;112(4):1382-91.
2008: Margaret A Park; Adly Yacoub; Devanand Sarkar; Luni Emdad; Mohamed Rahmani; Sarah Spiegel; Constantinos Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells.
Autophagy 2008;4(4):513-5.
2008: Margaret A Park; Adly Yacoub; Mohamed Rahmani; Guo Zhang; Lori Hart; Michael P Hagan; Stuart K Calderwood; Michael Y Sherman; Constantinos Koumenis; Sarah Spiegel; Ching-Shih Chen; Martin Graf; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
Molecular pharmacology 2008;73(4):1168-84.
2008: Adly Yacoub; Margaret A Park; Pankaj Gupta; Mohamed Rahmani; Guo Zhang; Hossein Hamed; David Hanna; Devanand Sarkar; Irina Lebedeva; Luni Emdad; Moira Sauane; Nicollaq Vozhilla; Sarah Spiegel; Constantinos Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.
Molecular cancer therapeutics 2008;7(2):297-313.
2007: Mohamed Rahmani; Tri K Nguyen; Paul Dent; Steven Grant
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Molecular pharmacology 2007;72(3):788-95.
2007: Mohamed Rahmani; Eric Maynard Davis; Timothy Ryan Crabtree; Joseph Reza Habibi; Tri K Nguyen; Paul Dent; Steven Grant
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
Molecular and cellular biology 2007;27(15):5499-513.
2007: Tri K Nguyen; Mohamed Rahmani; Hisashi Harada; Paul Dent; Steven Grant
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Blood 2007;109(9):4006-15.
2006: Ning Gao; Lora Kramer; Mohamed Rahmani; Paul Dent; Steven Grant
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Molecular pharmacology 2006;70(2):645-55.
2006: Tri K Nguyen; Mohamed Rahmani; Ning Gao; Lora Kramer; Amie S Corbin; Brian J Druker; Paul Dent; Steven Grant
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2239-47.
2006: Girija Dasmahapatra; Mohamed Rahmani; Paul Dent; Steven Grant
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Blood 2006;107(1):232-40.
2006: Ning Gao; Mohamed Rahmani; Xianglin Shi; Paul Dent; Steven Grant
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
Blood 2006;107(1):241-9.
2005: Mohamed Rahmani; Eric Maynard Davis; Cheryl Bauer; Paul Dent; Steven Grant
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
The Journal of biological chemistry 2005;280(42):35217-27.
2005: Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Molecular and cellular biology 2005;25(13):5429-44.
2005: Xin-Yan Pei; Yun Dai; Mohamed Rahmani; Weiqun Li; Paul Dent; Steven Grant
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4589-600.
2005: Ning Gao; Mohamed Rahmani; Paul Dent; Steven Grant
2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process.
Oncogene 2005;24(23):3797-809.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Lora B Kramer; Mei Huang; Richard Jove; Paul Dent; Steven Grant
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Molecular pharmacology 2005;67(4):1166-76.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Shawn G Payne; Paul Dent; Sarah Spiegel; Steven Grant
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Cancer research 2005;65(6):2422-32.
2005: Michael Hahn; Weiqun Li; Chunrong Yu; Mohamed Rahmani; Paul Dent; Steven Grant
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Molecular cancer therapeutics 2005;4(3):457-70.
2005: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Payal Khanna; Song Iy Han; Clint Mitchell; Paul Dent; Steven Grant
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Blood 2005;105(4):1706-16.
2004: Wesam Ahmed; Mohamed Rahmani; Paul Dent; Steven Grant
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
Cell cycle (Georgetown, Tex.) 2004;3(10):1305-11.
2004: Ning Gao; Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Molecular pharmacology 2004;66(4):956-63.
2004: Yun Dai; Mohamed Rahmani; Seth J Corey; Paul Dent; Steven Grant
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
The Journal of biological chemistry 2004;279(33):34227-39.
2004: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Paul Dent; Steven Grant
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Blood 2004;104(2):509-18.
2004: Chunrong Yu; Mohamed Rahmani; Paul Dent; Steven Grant
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Experimental cell research 2004;295(2):555-66.
2004: Sonia C Maggio; Roberto R Rosato; Lora B Kramer; Yun Dai; Mohamed Rahmani; David S Paik; Ann C Czarnik; Shawn G Payne; Sarah Spiegel; Steven Grant
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer research 2004;64(7):2590-600.
2004: Yun Dai; Xin-Yan Pei; Mohamed Rahmani; Daniel H Conrad; Paul Dent; Steven Grant
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Blood 2004;103(7):2761-70.
2004: Chunrong Yu; Mohamed Rahmani; Jorge A Almenara; Edward A Sausville; Paul Dent; Steven Grant
Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Oncogene 2004;23(7):1364-76.
2003: Mohamed Rahmani; Chunrong Yu; Yun Dai; Erin Reese; Wesam Ahmed; Paul Dent; Steven Grant
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Cancer research 2003;63(23):8420-7.
2003: Chunrong Yu; Mohamed Rahmani; Daniel Conrad; Mark Subler; Paul Dent; Steven Grant
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Blood 2003;102(10):3765-74.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Oncogene 2003;22(46):7108-22.
2003: Mohamed Rahmani; Chunrong Yu; Erin Reese; Wesam Ahmed; Karen Hirsch; Paul Dent; Steven Grant
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Oncogene 2003;22(40):6231-42.
2003: Chunrong Yu; Mark Subler; Mohamed Rahmani; Erin Reese; Geoffrey W Krystal; Daniel Conrad; Paul Dent; Steven Grant
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
Cancer biology & therapy 2003;2(5):544-51.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Cell cycle (Georgetown, Tex.) 2003;2(5):467-72.
2003: Wentao Jia; Chunrong Yu; Mohamed Rahmani; Geoffrey W Krystal; Edward A Sausville; Paul Dent; Steven Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Blood 2003;102(5):1824-32.
2003: Chunrong Yu; Mohamed Rahmani; Jorge A Almenara; Mark Subler; Geoffrey W Krystal; Daniel Conrad; Lubya Varticovski; Paul Dent; Steven Grant
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Cancer research 2003;63(9):2118-26.
2003: Chunrong Yu; Mohamed Rahmani; Yun Dai; Daniel Conrad; Geoffrey W Krystal; Paul Dent; Steven Grant
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Cancer research 2003;63(8):1822-33.
2002: Mohamed Rahmani; Steven Grant
UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937).
Cell cycle (Georgetown, Tex.) 2002;1(4):273-81.
2002: Mohamed Rahmani; Yun Dai; Steven Grant
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Experimental cell research 2002;277(1):31-47.
2002: Leanne Cartee; Rebecca Smith; Yun Dai; Mohamed Rahmani; Roberto R Rosato; Jorge A Almenara; Paul Dent; Steven Grant
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Molecular pharmacology 2002;61(6):1313-21.